PRODYGY is a Phase I/II study to assess the safety, tolerability, efficacy and quality of life following a single subretinal injection of SPVN06 in the worst-seeing eye of adult patients with RP due t...
Read moreThe Hospital del Mar Medical Research Institute is leading the study that will evaluate whether a new molecule can be used to improve the cognitive performance of people with Down syndrome.
Read moreFindings show that camizestrant, an oral next generation selective estrogen receptor degrader (ngSERD), significantly improves progression-free survival versus fulvestrant in patients with estrogen re...
Read moreEn los últimos dos años hemos vivido una transformación en la industria sanitaria, viendo como dos grandes industrias, independientes y en constante evolución, se acercaban hasta acabar convergien...
Read moreEl ensayo clínico GENIAL ha evaluado en humanos la eficacia de un suplemento con genisteína, un polifenol presente en la soja con efectos beneficiosos frente a enfermedades degenerativas
Read moreOryzon Genomics presents the final data from its Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the...
Read moreResearchers at Pulmobiotics, a start-up founded in 2020 at the Centre for Genomic Regulation (CRG) in Barcelona, have begun work on a ‘living medicine’ to improve the efficacy of lung cancer treat...
Read moreOryzon Genomics, S.A., announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV...
Read moreThe mission of the new drug is to block the LIF protein that is altered in various types of cancer, promoting the proliferation of tumor stem cells and deactivating the immune system's response agains...
Read moreLa nueva sociedad tiene por objetivo desarrollar, producir y comercializar una innovadora plataforma de fármacos basada en ARNs circulares artificiales (circRNAs) que permitirá la generación de nue...
Read moreCorify Care y GENESIS Biomed desarrollarán una plataforma tecnológica que utiliza mapeo no-invasivo, modelos matemáticos de corazón e inteligencia artificial para predecir efectos secundarios de l...
Read moreLos nuevos datos del ensayo de fase 1/2 ARROW, en el que ha participado la Dra. Elena Garralda, directora de la Unidad de Terapia Molecular del Cáncer (UITM) – CaixaResearch del Vall d’Hebron Ins...
Read more